2. GPCR/G Protein Metabolic Enzyme/Protease
  3. Prostaglandin Receptor Endogenous Metabolite
  4. Iloprost

Iloprost  (Synonyms: Ciloprost; ZK 36374)

Cat. No.: HY-A0096 Purity: 99.76%
COA Handling Instructions

Molarity Calculator

Iloprost (ZK 36374; Ciloprost) is a prostacyclin (PGI2) analogue, involves in embryo development and inflammation improvement, and inhibits tumor metastasis. Iloprost can be used for peripheral vascular research.

For research use only. We do not sell to patients.

Iloprost Chemical Structure

Iloprost Chemical Structure

CAS No. : 78919-13-8

Size Price Stock Quantity
Oil + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 748 In-stock
Solution
10 mM * 1 mL in DMSO USD 748 In-stock
Oil
2 mg USD 340 In-stock
5 mg USD 680 In-stock
10 mg USD 1100 In-stock
25 mg USD 2250 In-stock
50 mg USD 3500 In-stock
100 mg USD 5600 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Iloprost:

Iloprost Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Iloprost (ZK 36374; Ciloprost) is a prostacyclin (PGI2) analogue, involves in embryo development and inflammation improvement, and inhibits tumor metastasis. Iloprost can be used for peripheral vascular research[1][2][3][4].

IC50 & Target

IP

 

In Vitro

Prostacyclin (PGI2) is synthesised in oviductal fluid and enhance the embryo development[1].
Iloprost is an PGI2 analog, and affects maturation and developmental competence of bovine oocytes[1].
Iloprost (0.5 μM; 22-24 h) increases blastocyst rates of bovine embryos as well as proportion of expanded blastocysts[1].
Iloprost (0.5 μM; 22-24 h) assists maturation rates and cumulus cell expansion of bovine oocytes, and increases the mRNA expression of genes related to cumulus expansion[1].
Iloprost (0.5 μM; 22-24 h) reduces the occurrence of apoptosis in COCs and promotes an anti-apoptotic balance in the transcription of genes involved in apoptosis (BAX and BCL2) [1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Iloprost Related Antibodies

RT-PCR[1]

Cell Line: Bovine oocytes: cumulus oocyte complexes (COCs)
Concentration: 0.5 μM
Incubation Time: 22-24 hours
Result: Increased mRNA expression levels of cysteine proteinases cathepsins, including ADAM17, AREG, and TNFAIP6 23 and cathepsin genes (CTSK and CTSS).
In Vivo

Iloprost (0.3 mg/kg/min; via s.c. mini pumps; 33 d) has a significant anti-metastatic activity in a spontaneously metastasizing tumor model in rat[2].
Iloprost (0.2 mg/kg/d; i.p.; 10 d) attenuates hyperoxia effects and reduces inflammation in the newborn mouse lung, with Cyclooxygenase-2 (COX-2/PTGS2) mediates hyperoxia-induced impairment[3].
Iloprost (0.2 mg/kg; i.v. or i.p.) exhibits short half-life, and is often administered by means of frequent (every 2-4h) inhalation in treatment[4].
Comparison of pharmacokinetic parameter in rats and mice[4]

Animal Route Dose (mg/kg) AUC (ng•h/mL) F (%) CL (range) (mL/min/kg) t1/2λi (min) t1/2λz (min)
Mice i.v. 0.2 21.9 100 152 3 15
Rat i.g. 0.2 2.2 10 / 4 58

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Spontaneously metastasizing R 3327 MAT Lu prostate carcinoma in Cop rat[2]
Dosage: 0.3 mg/kg/min
Administration: Subcutaneous administration via Alzet mini pumps; continuously for 33 days
Result: Reduced the number of visible lung metastases, but had no effect on the growth of the primary tumor.
This action was based on the ability to reduce the attachment of tumor cells to platelets and to inhibit adhesion of tumor cells-platelet aggregates to the endothelial lining.
Animal Model: Newborn C57BL/6 mice (4-day-old)[3]
Dosage: 0.2 mg/kg
Administration: Intraperitoneal injection; once daily; 10 days
Result: Reduced markedly pro-inflammatory cytokines IL-1β and TNF-α mRNA and protein.
Inhibited alveolar septation, reduced hyperoxia-induced total lung resistance and myeloperoxidase, prevented hyperoxia-reduced lung microvascular density.
Clinical Trial
Molecular Weight

360.49

Formula

C22H32O4
CAS No.
Appearance

Oil

Color

Colorless to light yellow

SMILES

O=C(O)CCC/C=C1C[C@@]2([H])C[C@@H](O)[C@H](/C=C/[C@@H](O)C(C)CC#CC)[C@@]2([H])C\1
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Pure form -20°C 3 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (277.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.7740 mL 13.8700 mL 27.7400 mL
5 mM 0.5548 mL 2.7740 mL 5.5480 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.76%

COA (246 KB) HNMR (284 KB) LCMS (89 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.7740 mL 13.8700 mL 27.7400 mL 69.3501 mL
5 mM 0.5548 mL 2.7740 mL 5.5480 mL 13.8700 mL
10 mM 0.2774 mL 1.3870 mL 2.7740 mL 6.9350 mL
15 mM 0.1849 mL 0.9247 mL 1.8493 mL 4.6233 mL
20 mM 0.1387 mL 0.6935 mL 1.3870 mL 3.4675 mL
25 mM 0.1110 mL 0.5548 mL 1.1096 mL 2.7740 mL
30 mM 0.0925 mL 0.4623 mL 0.9247 mL 2.3117 mL
40 mM 0.0694 mL 0.3468 mL 0.6935 mL 1.7338 mL
50 mM 0.0555 mL 0.2774 mL 0.5548 mL 1.3870 mL
60 mM 0.0462 mL 0.2312 mL 0.4623 mL 1.1558 mL
80 mM 0.0347 mL 0.1734 mL 0.3468 mL 0.8669 mL
100 mM 0.0277 mL 0.1387 mL 0.2774 mL 0.6935 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Iloprost Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Iloprost78919-13-8Ciloprost ZK 36374ZK36374ZK 36374ZK-36374Prostaglandin ReceptorEndogenous MetabolitePGI2 analogin vitro maturationIVMembryo developmentanti-inflammationperipheral vascular diseasesanti-metastatictumor cell-platelet interactionin vitro fertilizationCyclooxygenase-2COX-2/PTGS2hyperoxia-induced impairmentInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Iloprost
Cat. No.:
HY-A0096
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.